We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.17B
1-Year Est. Return 92.19%
This Fund
S&P 500
This Quarter Est. Return
+32.88%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$1.17B
AUM Growth
+$68.7M
Cap. Flow
+$9.42M
Cap. Flow %
0.81%
Top 10 Hldgs %
33.9%
Holding
116
New
34
Increased
23
Reduced
41
Closed
18

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$26.9M
2
ASND icon
Ascendis Pharma A/S
ASND
+$19M
3
MTD icon
Mettler-Toledo International
MTD
+$16.1M
4
MRK icon
Merck
MRK
+$14.9M
5
CYTK icon
Cytokinetics
CYTK
+$13.8M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$50M
2
LLY icon
Eli Lilly
LLY
+$27.1M
3
PEN icon
Penumbra
PEN
+$25.8M
4
GKOS icon
Glaukos
GKOS
+$23.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 98.83%
2 Miscellaneous 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
51
CALL
Cencora
COR
$63.2B
$7.95M 0.68%
+28,100
New +$8.1M
IRTC icon
52
iRhythm Holdings
IRTC
$4.06B
$7.76M 0.67%
+65,196
New +$7.58M
KOD icon
53
Kodiak Sciences
KOD
$2.22B
$7.53M 0.65%
193,315
+78,596
+69% +$3.06M
ABT icon
54
Abbott
ABT
$187B
$7.46M 0.64%
82,230
-58,202
-41% -$5.31M
WST icon
55
West Pharmaceutical
WST
$23.9B
$7.44M 0.64%
+20,733
New +$6.34M
TAK icon
56
Takeda Pharmaceutical
TAK
$58.9B
$7.12M 0.61%
+444,173
New +$7.35M
HNGE
57
Hinge Health
HNGE
$7.45B
$6.88M 0.59%
+82,860
New +$4.5M
ARQT icon
58
Arcutis Biotherapeutics
ARQT
$3B
$6.35M 0.54%
+242,069
New +$5.64M
IART icon
59
Integra LifeSciences
IART
$1.3B
$6.26M 0.54%
+348,746
New +$4.88M
ILMN icon
60
Illumina
ILMN
$33B
$6.16M 0.53%
35,040
+6,171
+21% +$903K
MGTX icon
61
MeiraGTx Holdings
MGTX
$1.33B
$6.15M 0.53%
+455,286
New +$4.52M
OCS icon
62
Oculis Holding
OCS
$676M
$6.05M 0.52%
+436,042
New +$9.9M
NTRA icon
63
Natera
NTRA
$47.3B
$5.99M 0.51%
22,077
-37,927
-63% -$8.09M
ABVX
64
Abivax
ABVX
$10B
$5.77M 0.49%
43,264
+16,600
+62% +$1.88M
CNC icon
65
PUT
Centene
CNC
$33.1B
$5.66M 0.49%
+88,200
New +$4.72M
GH icon
66
Guardant Health
GH
$21.7B
$5.51M 0.47%
+36,701
New +$3.99M
CELC icon
67
Celcuity
CELC
$4.68B
$5.46M 0.47%
+52,155
New +$6.02M
BLTE
68
Belite Bio
BLTE
$7.8B
$5.36M 0.46%
34,803
-24,629
-41% -$3.77M
GPCR icon
69
Structure Therapeutics
GPCR
$3.38B
$4.91M 0.42%
91,550
-34,833
-28% -$1.54M
RCUS icon
70
Arcus Biosciences
RCUS
$3.78B
$4.69M 0.4%
+152,129
New +$3.76M
CRL icon
71
Charles River Laboratories
CRL
$13.8B
$4.25M 0.36%
+18,747
New +$3.34M
ELAN icon
72
Elanco Animal Health
ELAN
$12.2B
$4.24M 0.36%
+172,489
New +$3.99M
ARGX icon
73
argenx
ARGX
$64.6B
$4.16M 0.36%
4,482
-53
-1% -$43.7K
BIO icon
74
Bio-Rad Laboratories Class A
BIO
$10.3B
$4.11M 0.35%
+13,995
New +$3.97M
SYRE icon
75
Spyre Therapeutics
SYRE
$7.85B
$4.1M 0.35%
+46,217
New +$3.37M
1 2
3
4 5

Similar funds

JC
Jacobs & Co San Francisco, California $1.17B AUM 37.3% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
MK
MASTERINVEST Kapitalanlage Vienna $1.16B AUM 40% 1-Year Est. Return
HCP
Hiddenite Capital Partners New York $1.16B AUM 95.58% 1-Year Est. Return
EC
Estate Counselors Thiensville, Wisconsin $1.16B AUM 21.97% 1-Year Est. Return
M
MOTCO San Antonio, Texas $1.17B AUM 23.84% 1-Year Est. Return
CCM
Coliseum Capital Management Rowayton, Connecticut $1.16B AUM 23.26% 1-Year Est. Return
VFP
Verus Financial Partners Richmond, Virginia $1.17B AUM 15.91% 1-Year Est. Return

PFM Health Sciences's Q2 2026 Portfolio in Review

As of Q2 2026, PFM Health Sciences held 116 positions worth $1.17B, up 6.3% from $1.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences's Q2 2026 filing shows 34 new, 23 increased, 41 reduced and 18 closed positions. Its largest new stake was Humana: 94,375 shares worth $37.5M. The largest sale was Tenet Healthcare, an estimated $50M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • PFM Health Sciences's largest Q2 2026 buy was Humana: 94,375 shares worth $37.5M.
  • PFM Health Sciences added most to Ascendis Pharma A/S in Q2 2026, an estimated $19M increase.
  • PFM Health Sciences's biggest Q2 2026 reduction was Tenet Healthcare, cutting an estimated $50M.
  • PFM Health Sciences fully exited Glaukos in Q2 2026, selling an estimated $23.2M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $1.17B portfolio in Q2 2026.
  • PFM Health Sciences opened 34 new positions and closed 18 in Q2 2026.
  • PFM Health Sciences's portfolio value rose 6.3% quarter-over-quarter to $1.17B.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.